

Special Issue

Impact of Immunization Safety Monitoring on Vaccine Coverage

Message from the Guest Editor

Despite progress in immunization recovery, immunization coverage remains lower than before the COVID-19 pandemic. Global immunization stakeholders have committed to achieving immunization recovery and reaching zero-dose communities. They are focusing their efforts on raising vaccination levels and protecting vulnerable and special populations from vaccine-preventable diseases. In addition to ensuring equitable access to immunizations, it is essential to consider immunization safety concerns, as they are a significant driver of vaccine hesitancy. This Special Issue aims to highlight immunization safety in improving immunization coverage. We welcome original research articles and reviews focusing on research areas that include disparities in immunization coverage, immunization safety, active vaccine safety surveillance, adverse events following immunization, digital innovations for immunization program monitoring, barriers to reporting immunization safety events, advances to address immunization safety information and strategies to increase the demand for vaccines.

Guest Editor

Dr. Jane F. Gidudu

Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA

Deadline for manuscript submissions

25 August 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/198961

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).